ReviewOxidative medicine and cellular longevity2020
New Approaches to Identify Sepsis Biomarkers: The Importance of Model and Sample Source for Mass Spectrometry.
Review in Oxidative medicine and cellular longevity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Exploring proteomic signatures in sepsis and non-infectious systemic inflammatory response syndrome.PloS one · 2026Observational
- Comparison of the accuracy of procalcitonin, neutrophil CD64, and C-reactive protein for the diagnosis and prognosis of septic patients after antibiotic therapy.Practical laboratory medicine · 2025Article
- Clinical glycoproteomics: methods and diseases.MedComm · 2024Review
- Combination of HBA1, TTR, and SERPINF2 in plasma defines phenotype correlated with severe burn outcome.iScience · 2023Article
- An appraisal of studies using mouse models to assist the biomarker discovery for sepsis prognosis.Heliyon · 2023Review
- Review
- Endotoxin in Sepsis: Methods for LPS Detection and the Use of Omics Techniques.Diagnostics (Basel, Switzerland) · 2022Review
- Compliance with SEP-1 guidelines is associated with improved outcomes for septic shock but not for severe sepsis.Journal of intensive medicine · 2022Article
- Future Perspectives in the Diagnosis and Treatment of Sepsis and Septic Shock.Medicina (Kaunas, Lithuania) · 2022Article
- Proteomic Approaches to Unravel Mechanisms of Antibiotic Resistance and Immune Evasion of Bacterial Pathogens.Frontiers in medicine · 2022Review
- The Secretome Deregulations in a Rat Model of Endotoxemic Shock.Oxidative medicine and cellular longevity · 2021Article
- Evaluation of the Molecular Mechanisms of Sepsis Using Proteomics.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Septic shock is a systemic inflammatory response syndrome associated with circulatory failure leading to organ failure with a 40% mortality rate. Early diagnosis and prognosis of septic shock are necessary for specific and timely treatment. However, no predictive biomarker is available. In recent years, improvements in proteomics-based mass spectrometry have improved the detection of such biomarkers. This approach can be performed on different samples such as tissue or biological fluids. Working directly from human samples is complicated owing to interindividual variability. Indeed, patients are admitted at different stages of disease development and with signs of varying severity from one patient to another. All of these elements interfere with the identification of early, sensitive, and specific septic shock biomarkers. For these reasons, animal models of sepsis, although imperfect, are used to control the kinetics of the development of the pathology and to standardise experimentation, facilitating the identification of potential biomarkers. These elements underline the importance of the choice of animal model used and the sample to be studied during preclinical studies. The aim of this review is to discuss the relevance of different approaches to enable the identification of biomarkers that could indirectly be relevant to the clinical setting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.